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Abstract
Approximately 7%–10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney
replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in
pressure and volume parameters is an important differentiation between PD and in-center hemodialysis.
However, the burden of hypertension and prognostic association of BP with mortality follow comparable
patterns in both modalities. Although management of hypertension uses similar therapeutic principles,
long-term preservation of residual diuresis and longevity of peritoneal membrane function require
particular attention in the prescription of the appropriate dialysis regimen among those on PD. Dietary
sodium restriction, appropriate use of icodextrin, and limited exposure of peritoneal membrane to
bioincompatible solutions, as well as adaptation of the PD regimen to the peritoneal transport
characteristics, are first-line therapeutic strategies to achieve adequate volume control with a potential long-
term benefit on technique survival. Antihypertensive drug therapy is a second-line therapeutic approach,
used when BP remains unresponsive to the above volume management strategies. In this article, we review
the available evidence on epidemiology, diagnosis, and treatment of hypertension among patients on PD
and discuss similarities and differences between PD and in-center hemodialysis. We conclude with a call
for randomized trials aiming to elucidate several areas of uncertainty in management of hypertension in the
PD population.
Keywords: peritoneal dialysis, end stage kidney disease, icodextrin, blood pressure, renal dialysis, Sodium,
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Introduction
The continuous nature of kidney replacement therapy is considered as major advantage of peritoneal
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dialysis (PD) over hemodialysis (HD) (1). Nonetheless, epidemiology of hypertension appears to be similar
in both modalities because elevated or uncontrolled BP is highly prevalent among patients on PD and is
associated with mortality (2–4). Although hypertension in PD is managed using similar therapeutic
strategies with those applied in HD (2), there are also some differences that require attention. For example,
volume management in PD should take into consideration the value of preservation of residual kidney
function and longevity of peritoneal membrane function (5).
In this article, we provide an overview of epidemiology, diagnosis, and management of hypertension in PD.
We discuss similarities and differences between PD and in-center HD and provide directions for future
research in these important areas.
Epidemiology
Prevalence and Control of Hypertension
Earlier studies suggested that hypertension might be more adequately controlled in PD than in HD. The
1995 Peritoneal Dialysis Core Indicators Study reported that among 1202 patients on PD, only 29% had
systolic BP >150 mm Hg and 18% had diastolic BP >90 mm Hg (6). In contrast, a study enrolling 2535
patients on HD in the United States showed that hypertension affected up to 86% of study participants (7).
Subsequent studies showed a high burden of hypertension in PD. The Italian Co-operative Peritoneal
Dialysis Study Group reported that among 504 patients on PD, the prevalence of hypertension was 88%,
using the World Health Organization/International Society of Hypertension (WHO/ISH) diagnostic criteria
(8). Uncontrolled clinic BP ≥140/90 mm Hg was detected in 79% of drug-treated hypertensives. Using
ambulatory BP monitoring, 77% of drug-treated hypertensives had poor BP control, indicating a high
burden of hypertension (8).
The natural course of hypertension was retrospectively evaluated in 207 patients on incident PD (9). Using
the WHO/ISH criteria, hypertension was prevalent in 93% of participants at initiation of PD.
Longitudinally, BP was improved and reached a nadir during the first 6–12 months of follow-up; thereafter,
a progressive deterioration in BP control was evident. Older age, severity of preexisting hypertension, and
loss of residual kidney function were determinants of deterioration in BP control (9).
Ambulatory BP Patterns in Patients on PD versus Patients on HD
In a cosinor model analysis of 11,833 BP measurements obtained during 44-hour ambulatory BP
monitoring in 125 patients on HD, increments in interdialytic weight gain were associated with higher
linear increase and blunted circadian amplitude of BP between dialysis treatments (10). These volume-
mediated alterations in the ambulatory BP rhythms may be less prominent in PD, owing to the “steady”
volume state of these patients. Luik et al. (11) showed no difference in diurnal BP variation when 20
patients on continuous ambulatory peritoneal dialysis (CAPD) were compared with 20 patients on HD.
Rodby et al. (12) showed that the circadian pattern of 48-hour BP was not different in a comparison of 27
patients on CAPD with 33 patients on HD. However, patients on HD had higher 48-hour BP levels and BP
loads (12). By contrast, Tonbul et al. (13) showed that the average 44-hour BP levels and loads were
similar between 24 patients on CAPD and 22 patients on HD. Daytime BP during the dialysis-on day was
lower in patients on HD than in patients on CAPD; the reverse phenomenon occurred during the dialysis-
off day (13). Larger head-to-head comparisons are warranted to elucidate similarities and differences in
ambulatory BP between HD and PD.
BP Control in Patients on CAPD versus Patients on Automated Peritoneal Dialysis
Frequent night-time and long daytime dwells may interfere with peritoneal sodium removal, suggesting a
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less effective BP control in automated peritoneal dialysis (APD) compared with CAPD (1). Comparative
studies showed that BP levels, antihypertensive drug use, the presence of pedal edema, and extracellular
body water assessed with bioelectric impendence analysis (BIA) are not different between the two
modalities (14). Studies using ambulatory BP monitoring suggested that 24-hour BP loads and diurnal BP
variation are comparable between APD and CAPD (15). These observations, however, are derived from
small, cross-sectional studies without appropriate matching between comparison groups.
The Association of BP with Mortality
Similar to the U-shaped association of peridialytic BP with mortality among patients on HD (16), cohort
studies showed that clinic BP is inversely associated with mortality in patients on PD (Table 1) (4,17,18).
This “reverse” epidemiology of hypertension may be explained by a number of factors that confound the
association of high BP with mortality risk. In a cohort of 2770 patients on incident PD, each 10-mm Hg
higher systolic BP was associated with 16% lower risk for all-cause mortality over the first year of follow-
up (4). However, higher systolic BP was associated with excess risk for late mortal events, suggesting that
dialysis vintage modifies the association of BP with mortality (4). The level of illness and severity of
comorbidities with opposing effect on BP is another factor that affects the predictive value of hypertension.
In a cohort of 77 patients on PD, when the analysis was adjusted for severity of congestive heart failure, the
inverse association of lower systolic BP with excess mortality risk was mitigated (17). By contrast, the
pulsatile component of BP provides a more direct mortality signal (3,19). The linear association of higher
pulse pressure with mortality is possibly reflecting a state of accelerated arterial stiffening in ESKD. Lastly,
the epidemiology of hypertension may vary considerably if out-of-office BP recordings are used as risk
predictors. Among patients on HD, home and ambulatory BP recordings are linearly associated with excess
mortality (16). Prospective studies are warranted to elucidate the prognostic significance of out-of-office
BP recordings in PD.
The optimal BP targets among dialysis patients remain unknown. The reverse association of clinic BP with
mortality in observational studies in contrasted by meta-analyses of randomized trials showing that
deliberate BP lowering with antihypertensive drugs is associated with improvement in clinical outcomes
(16). The feasibility and safety of BP lowering is also supported by the BP in Dialysis trial (20), in which
126 hypertensive patients on HD were randomized to an intensive, predialysis systolic BP target of
110–140 mm Hg versus a standard target of 155–165 mm Hg. Intensive BP lowering did not aggravate the
incidence of major cardiovascular adverse events, hospitalizations, or vascular access thromboses (20).
Larger, phase 3 trials evaluating “hard” clinical end points are warranted to define optimal BP targets. Until
such evidence become available, we encourage the wider use of out-of-office BP monitoring as an
approach to optimize risk stratification, and we support the current International Society of Peritoneal
Dialysis (ISPD) recommended target of <140/90 mm Hg for self-measured home BP (5).
Diagnosis
The optimal method to diagnose hypertension, detect the presence of target organ damage, and
prognosticate the risk of mortality in patients on PD is an area of controversy. The availability of home BP
recordings routinely taken by patients on PD offers the advantage of using a theoretically superior BP-
monitoring technique in hypertension management (2). Studies comparing the diagnostic accuracy of
different BP-monitoring techniques are summarized in Table 2, and suggest that routine BP recordings
taken by the patients themselves at home are worse than standardized clinic BP in approximating daytime
ambulatory BP and in detecting evidence of target organ damage (21–23); this discrepancy is possibly
explained by the absence of standardized protocols for home BP monitoring. Similarly to nondialysis
populations, ambulatory BP monitoring is the gold-standard method in management of hypertension in PD
(2). Using this method, the aforementioned Italian Co-operative Peritoneal Dialysis Study uncovered a
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Definitions.
Assessment.
nondipping status in 53% of 504 participants (8), confirming the high prevalence of nocturnal hypertension
in this population. Owing to the low availability of ambulatory BP monitoring, we recommend the use of
office BP measurements as the standard of care, and encourage the wide use of validated BP monitors as an
approach to optimize the diagnostic accuracy of home BP recordings (2). Additional research is warranted
in this area because currently available studies are small and underpowered.
Management of Volume
The first step in management of hypertension is the adequate clinical assessment of volume status (Figure 1
). The ISPD guidelines (5) mandate the recognition and control of volume overload as first-line therapy of
hypertension.
The Concept of Dry Weight
The concept of dry weight is introduced as an approach to recognize subclinical volume
expansion (2). Management of dry weight in patients on HD is on the basis of the gentle and gradual
reduction of postdialysis weight until patients reach an “ideal” weight at which there will be no
signs/symptoms of hypervolemia or hypovolemia (2). In the Dry Weight Reduction in Hypertensive
Hemodialysis Patients trial (24), dry weight reduction of 0.9 kg over an 8-week period provoked a
reduction of 6.6/3.3 mm Hg in interdialytic BP. Despite the obvious differences between HD and PD, the
concept of dry weight is similarly applicable to those on PD. Signs/symptoms reflecting hypovolemia
should be carefully monitored when managing volume in patients on PD (2).
With the exception of patients presenting with clinically overt volume overload, the
assessment of volume status using standard clinical diagnostic criteria is difficult. In the Brazilian
Peritoneal Dialysis Multicenter study (25), the presence of pedal edema was able to detect volume
expansion only in 28% out of 1089 patients on PD. Similarly, the presence of pedal edema is an insufficient
tool to detect volume overload in asymptomatic patients on HD (26). Studies using more objective
technologies showed that the prevalence of subclinical volume expansion among patients on PD is higher
and clinical judgement is insufficient to determine whether patients are truly euvolemic. In the European
Body Composition Monitoring study (27), BIA uncovered that only 40% out of 639 patients on PD were
euvolemic (27). Standard clinical characteristics commonly used in dry weight assessment, such as urine
output, peritoneal ultrafiltration, and BP levels, were unable to detect volume expansion (27). In a Chinese
cohort of 307 patients on PD, BIA identified subclinical volume expansion in 67% of study participants
(28). Among 1092 patients on PD participating in the Initiative of Patient Outcomes in Dialysis study (29),
BIA showed that subclinical overhydration was detectable in 57% of participants (29). In a meta-analysis
of 42 cohort studies (incorporating data from 60,790 patients on dialysis), a BIA-derived overhydration
index >15% was associated with 2.28-fold higher risk for all-cause mortality (30). Among 88 patients on
PD having their volume status assessed with lung ultrasound, moderate to severe lung congestion was
detected in 46% of participants (31). The presence of pedal edema or dyspnea had poor accuracy in
detecting lung congestion.
Whether the above technologies aid the achievement of euvolemia remains unclear. This hypothesis was
explored in a pilot study, in which 160 patients on PD were randomized to BIA-guided volume
management versus standard care (32). Significant reductions in extracellular-to-intracellular volume ratio
were noted during the 3-month follow-up in the intervention group. By contrast, the United Kingdom-
Shanghai and Control of Fluid Balance Guided by Body Composition Monitoring in Patients on Peritoneal
Dialysis trials showed that BIA-guided volume management did not reduce extracellular body water and
had no benefit on BP control or regression of left ventricular (LV) hypertrophy (33). In a 2017 meta-
analysis of seven randomized trials, BIA-guided volume management was associated with a modest
reduction of 2.73 mm Hg in systolic BP that was not translated into improvement in all-cause mortality
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(34). The ongoing Lung Water by Ultra-Sound Guided Treatment to Prevent Death and Cardiovascular
Complications in High Risk ESKD Patients with Cardiomyopathy Trial is planning to recruit 500 high-risk
patients on HD, aiming to compare the effect of guiding volume management with lung ultrasound versus
standard care on a composite outcome of all-cause mortality, myocardial infarction, or worsening
congestive heart failure. Randomized trials are warranted to elucidate the role of these techniques in
patients on PD as well.
Dietary Sodium Restriction
Nonadherence to a sodium-restrictive diet is a major driver of thirst and fluid intake (1). Dietary sodium
intake is recommended not to exceed 2 g daily (corresponding to 5 g of sodium chloride) (2). Improvement
in total body sodium balance may facilitate the achievement of adequate volume control. Although this
notion is not supported by clinical trial evidence, observational studies have shown significant BP lowering
in response to a therapeutic strategy incorporating dietary sodium restriction alone or combined with
enhanced ultrafiltration (35). Such an approach, however, may be associated with more rapid decline in
residual kidney function, whereas other observational studies have associated low-sodium intake with
higher mortality, possibly mediated through deficient protein and nutrient intake (36).
Adjunctive Use of Diuretics
Longer preservation of residual kidney function arising from gentle and continuous kidney replacement
therapy is a potential advantage of PD over in-center HD. A post hoc analysis of the Canada-United States
study showed that each 250-ml increment in urine volume was associated with 36% lower risk for all-cause
mortality (37). Administration of loop diuretics may enhance urine output and fractional urinary excretion
of sodium, facilitating the maintenance of fluid balance among patients on PD with preserved residual
kidney function (1). In a randomized trial enrolling 61 incident patients on PD, compared with no
treatment, administration of furosemide (250 mg/d) for 12 months increased 24-hour urine output and
urinary sodium excretion, but had no protective effect on preservation of residual kidney function (38).
Whether intensification of diuretic therapy is beneficial or incremental among patients on PD with residual
diuresis warrants investigation in future trials.
Adaptation of the Dialysis Regimen to the Peritoneal Transport Characteristics
Volume overload and poor BP control may arise in patients receiving a PD regimen that is inappropriately
adapted to their peritoneal transport characteristics (39). Longer dwells in fast transporters limit
ultrafiltration because of a rapid dissipation of glucose gradient. Observational studies showed that fast
transporters had higher 24-hour BP, abnormal circadian BP patterns, and higher LV mass index than low
transporters (40). Observational studies showed that fast transporting status was independently associated
with higher mortality risk (41), an association possibly explained by sodium and water reabsorption when
long dwells with glucose-containing solutions are prescribed to fast transporters. In this setting, transfer to
APD should be considered (1). By contrast, shorter dwells in low transporters limit net diffusive sodium
removal because of sodium sieving. Midday exchanges with glucose-containing solutions or icodextrin
during the long daytime dwell enhance sodium removal in APD (1).
Patients with substantial residual diuresis may benefit from less intensive regimens, such as dry night in
CAPD and partially or fully dry day in APD (1). However, loss of residual kidney function represents a
silent cause of volume overload. In this setting, intensification of PD, avoidance of dry periods, increasing
dialysate glucose concentration, and appropriate use of icodextrin are therapeutic options to maintain
euvolemia (1).
Icodextrin Solution
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Low-Sodium Solutions.
Biocompatible Solutions.
Hypertonic glucose-containing solutions, although possibly effective in providing short-term volume
control, are associated with a number of adverse effects on residual kidney function, metabolic profile,
peritoneal membrane function, and technique longevity (1). Icodextrin, a starch-derived glucose polymer, is
widely used as alternative osmotic agent during the long overnight dwell in CAPD or during the long
daytime dwell in APD (1). The advantages of icodextrin include the intensification of peritoneal
ultrafiltration, protection of peritoneal membrane from the formation of advanced glycation end-products,
and neutral effect on metabolic profile (1). In a meta-analysis of 12 randomized trials (42), compared with
glucose-containing solutions, icodextrin enhanced net peritoneal ultrafiltration (weighted mean difference,
448.5 ml/d; 95% confidence interval, 289.3 to 607.8 ml/d) and reduced the incidence of overhydration
(relative risk, 30%; 95% confidence interval, 15% to 59%) (42) without compromising residual kidney
function.
Randomized trials tested also the hypothesis that the benefit of icodextrin on volume status may be
accompanied by a parallel BP-lowering effect (43–47) (Table 3). A crossover study of 14 patients on APD
compared icodextrin with standard 2.27% glucose solutions, both administered during the daytime dwell.
Over a 4-week follow-up period, icodextrin reduced office BP by 19.5/6.0 mm Hg despite the reduction in
antihypertensive medications in six out of 14 participants (47). In a double-blind trial, 50 hypertensive
patients on PD were randomized to icodextrin or 2.27% glucose solutions during the long dwell for 6
months (43). Despite the absence of a significant reduction in ambulatory BP, icodextrin-treated
participants required fewer antihypertensive medications to achieve BP control (43). Another trial
randomized 59 diabetic patients on CAPD to icodextrin or 2.27% glucose solutions during the overnight
dwell for 12 months (45). A BP-lowering effect was noted in icodextrin-treated participants, but not in
those assigned to glucose-containing solutions; this effect was confirmed with ambulatory BP monitoring
(48). Adequately powered randomized trials are required to elucidate the BP-lowering effect of icodextrin.
Others
Sodium removal in PD is achieved through convection with ultrafiltration as well
as through diffusive transperitoneal sodium elimination (1). Dialysate sodium in currently available PD
solutions is standardized to a concentration of 132–134 mmol/L, allowing only a small amount of diffusive
sodium transport. Earlier interventional studies using low (120 mmol/L) or ultra-low (98 mmol/L) dialysate
sodium showed that this approach enhances the diffusive removal but compromises convective elimination
(49). Studies combining low-sodium dialysate with higher dialysate glucose concentrations to compensate
for reduced osmolality showed that this intervention maintains peritoneal ultrafiltration, improves hydration
status, and provokes significant reductions in ambulatory BP (50). The noninferiority of low-sodium (125
mmol/L) versus standard-sodium PD solutions (134 mmol/L) on dialysis adequacy (defined as a between-
group difference of −0.5 in weekly total Kt/V urea) was tested in a recent trial enrolling 108 hypertensive
patients on CAPD (51). This trial failed to prove the noninferiority of low-sodium solutions because total
Kt/V urea was 2.53±0.89 in the low-sodium group versus 2.97±1.58 in the standard-sodium group (51).
However, low-sodium dialysate enhanced diffusive sodium removal by 1.188 g/d. A significant between-
group difference of −8.6/−4.6 mm Hg in office BP was noted at study completion. It has to be noted,
however, that low-sodium dialysate solutions are not yet commercially available and the aforementioned
results warrant investigation in phase 2 trials using ambulatory BP monitoring.
Neutral pH, low-glucose degradation product solutions are introduced as
alternative to standard glucose-containing solutions on the basis that their higher biocompatibility may
limit peritoneal membrane injury (1). In a meta-analysis of 18 randomized trials, biocompatible solutions
were associated with longer preservation of residual kidney function, particularly when their administration
was extended for >12 months (42). However, biocompatible solutions were ineffective in enhancing
peritoneal ultrafiltration assessed in 4-hour peritoneal equilibration tests. Similarly, 24-hour peritoneal
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ultrafiltration was not different between biocompatible and glucose-containing solutions (42).
Biocompatible solutions are not yet available in the United States.
Pharmacologic Management
Pathophysiology of hypertension in PD is complex and includes several nonvolume-dependent mechanistic
pathways (2). When BP remains uncontrolled despite the adequate management of volume,
antihypertensive therapy is the next treatment consideration to control BP.
The association of agents blocking the renin-angiotensin-aldosterone system (RAAS) with survival was
evaluated in a prospective cohort of 306 incident patients on PD (52). Over a total follow-up of 8422
patient months, RAAS blockade use was associated with 62% lower risk for all-cause mortality (52). As
shown in Table 4, pilot randomized trials are also suggestive of a beneficial effect of RAAS blockers on
intermediate end points, including short-term BP variability, LV hypertrophy, and arterial stiffness (53–56).
A 2014 meta-analysis of six randomized trials showed that compared with other antihypertensive drug
categories, RAAS blockers were associated with slower decline in residual kidney function (57).
The efficacy and safety of mineralocorticoid receptor antagonists among patients on PD was explored in
three randomized trials, summarized in Table 5 (58–60). These pilot trials suggest that add-on therapy with
mineralocorticoid receptor antagonists is associated with improvement in LV mass index and LV ejection
fraction, without a significant increase in the incidence of hyperkalemia. The wide use of spironolactone
and eplerenone among patients on PD should be avoided in anticipation of larger trials evaluating hard
clinical end points.
In conclusion, epidemiology of hypertension in PD appears to follow similar patterns with the burden and
prognostic significance of hypertension in in-center HD. The fact that PD is a home-based dialytic modality
suggests that home BP monitoring should be widely applied as a technique with additive diagnostic and
prognostic value to that of office BP recordings. Dietary sodium restriction, adjunctive use of diuretics,
appropriate use of icodextrin, and adaptation of the PD regimen to the peritoneal transport characteristics
are first-line volume management strategies with potential benefits on patient and technique survival.
Antihypertensive therapy is recommended only when hypertension remains uncontrolled despite the
adequate management of volume. Although small, randomized trials are suggestive of a beneficial effect of
RAAS blockers on intermediate end points, the comparative effectiveness of different antihypertensive
drug classes on hard clinical outcomes is unknown. Randomized trials rather than observational studies are
needed to elucidate several areas of uncertainty in management of hypertension among patients on PD.
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Table 1.
Longitudinal studies exploring the association of BP with mortality among patients on peritoneal
dialysis
Author Year N Follow-
Up, mo
Age,
yr
Baseline
BP, mm Hg
% of Patients on
Antihypertensive
Therapy
Association of BP with
all-cause mortality
Goldfarb-
Rumyantzev et
al. (18)
2005 1053 23 57.2 141.7/79.9 82 ↓ office systolic BP
associated with ↑ all-cause
mortality
Liu et al. (19) 2008 153 30 54.5 Median
pulse
pressure: 56
NA ↑ office pulse pressure
associated with ↑ all-cause
mortality
Fang et al. (3) 2009 306 21 59.4 Mean pulse
pressure:
56.8
83.3 ↑ office pulse pressure
associated with ↑ all-cause
mortality
Udayaraj et al.
(4)
2009 2770 45 58.0 143.1/81.4 NA ↑ office systolic BP
associated with ↓ early all-
cause mortality ↑ office
systolic BP associated with
↑ late all-cause mortality
Afshinnia et al.
(17)
2016 77 35 51.0 NA 89.6 ↑ office systolic BP
associated with ↑ all-cause
mortality after adjustment
for the severity of
congestive heart failure
↓ , lower; ↑, higher; NA, not available.
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Table 2.
Studies evaluating the diagnostic accuracy of different BP-monitoring techniques among patients on
peritoneal dialysis
Author Year N Test Method Reference
Method
Study Results
Wang et al. (23) 2001 31 Clinic BP 10-d
morning home
BP
Ambulatory
BP monitoring
The association of clinic systolic BP with
daytime systolic BP (r=0.81; P<0.05) was
stronger than the association of home systolic
BP with daytime systolic BP (r=0.62; P<0.05)
Koc et al. (21) 2002 74 Clinic BP Ambulatory
BP monitoring
24-h ambulatory BP could detect the presence
of LV hypertrophy, whereas clinic BP had no
association with indices of target organ damage
O’Shaughnessy
et al. (22)
2013 17 Clinic BP
BpTRU-derived
BP  7-d morning
home BP
Ambulatory
BP monitoring
Home systolic BP overestimated daytime
systolic BP by 14.2 mm Hg (95% CI, 4.3 to
21.4 mm Hg); routine clinic BP and BpTRU-
derived BP could better approximate daytime
BP
LV, left ventricular; 95% CI, 95% confidence interval.
BpTRU records BP automatically without an observer.
a
a
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Figure 1.
Volume control as first-line therapeutic approach of hypertension among patients on PD. Diagnosis and management
of hypertension among patients on PD should be on the basis of out-of-office BP monitoring. Given the poor diagnostic
accuracy of conventional office BP recordings and limited availability of ambulatory BP monitoring, we recommend the
wide use of home BP recordings taken by the patients themselves, with validated automated BP monitors as an alternative
approach to confirm diagnosis and guide the overall management of hypertension. Management of hypertension should
firstly be relied on adequate control of sodium and volume excess. Lowering dietary sodium intake, appropriate use of
loop diuretics in the presence of substantial residual kidney function, adaptation of dialysis regimen to peritoneal
transporting status, and use of icodextrin solutions during long daytime dwell in APD or during the long overnight dwell in
CAPD are first-line volume management strategies. Antihypertensive drug therapy should be initiated when hypertension
remains uncontrolled despite the adequate management of volume. Choice of the appropriate antihypertensive regimen
should be individualized, taking into consideration the comorbidities and overall risk profile of each patient. Although
comparative efficacy and safety of different antihypertensive drug categories among patients on PD remains elusive, some
clinical studies suggest that angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) exert
beneficial effects on a number of intermediate clinical end points, including long-term preservation of residual kidney
function. CCB, calcium-channel-blockers; CCPD, continuous cyclic peritoneal dialysis; Na, sodium.
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Table 3.
Randomized trials comparing the effect of icodextrin versus glucose-containing dialysate solutions
on BP in patients on peritoneal dialysis
UF, ultrafiltration; APD, automated peritoneal dialysis; ↓ , significant reduction in icodextrin groups relative to control
group; CAPD, continuous ambulatory peritoneal dialysis.
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Table 4.
Randomized trials evaluating the effect of angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in patients receiving peritoneal dialysis
PD, peritoneal dialysis; HR, hazard ratio; 95% CI, 95% confidence interval; LV, left ventricular; ACEIs, angiotensin-
converting enzyme inhibitors; ARBs, angiotensin receptor blockers; baPWV, brachial-ankle pulse wave velocity.
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Table 5.
Randomized trials evaluating the effect of mineralocorticoid receptor antagonists among patients on
peritoneal dialysis
Author Year N Characteristics Design Intervention Follow-
Up, mo
Primary
Outcome
Overall
Effect
Details
Taheri
et al.
(60)
2012 18 Patients on PD
with congestive
heart failure
and LV ejection
fraction ≤45%
Double-
blind
Spironolactone
(25 mg every
other day)
versus placebo
6 Change in LV
ejection
fraction
Better Spironolactone
therapy
improved
LVEF relative
to placebo
(25.7%±7.3%
versus
33.3%±7.8%;
P=0.002)
Ito et
al. (58)
2014 158 Patients on PD
without
congestive
heart failure
already treated
with ACEIs or
ARBs
Open-
label
Add-on
spironolactone
(25 mg/d)
versus no
treatment
24 Change in LV
mass index
Better Compared
with placebo,
add-on
spironolactone
improved LV
mass index at
6, 18, and 24
mo of follow-
up
Lin et
al. (59)
2016 253 Patients on HD
or PD without
congestive
heart failure
Open-
label
Add-on
spironolactone
(25 mg/d)
versus placebo
24 Death from
cardiovascular
events,
aborted
cardiac arrest,
or sudden
death
Better Spironolactone
lowered the
incidence of
the primary
outcome by
58% compared
with placebo
(HR, 42%;
95% CI, 26%
to 78%)
PD, peritoneal dialysis; LV, left ventricular; LVEF, left ventricular ejection fraction; ACEIs, angiotensin-converting
enzyme inhibitors; ARBs, angiotensin receptor blockers; HD, hemodialysis; HR, hazard ratio; 95% CI, 95%
confidence interval.
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